Losartan for corneal scar treatment
Part of Brain & nervous system, Eyes & vision, Injuries & trauma clinical trials.
This trial tests if losartan, a common blood pressure medicine, can help reduce corneal scars. It may be an option for adults with a stable corneal scar that has been present for at least one month.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have a corneal scar that has been there for at least 1 month
- Your scar is stable (no active sores or raw spots on the cornea)
- You have not had active treatment for the condition causing the scar for at least 1 month
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if the oral medication losartan can reduce scarring after ACL reconstruction surgery. Losartan is a blood pressure drug that may also help prevent scar tissue, potentially improving recovery.
This study tests whether losartan, a blood pressure medicine, can prevent excessive scar tissue (arthrofibrosis) after a total knee replacement. Participants receive losartan or a placebo for 6 months after surgery to see if it improves knee motion and reduces stiffness.
This trial tests if losartan, a blood pressure medication, can improve healing and recovery after surgery for a multi-ligament knee injury. Taking losartan for 30 days after surgery may reduce stiffness and help you get back to your normal activities sooner.
This trial tests a new eye drop to see if it can safely and effectively reduce corneal scars. It is for people who have a recent corneal injury (within the last month) that resulted in a scar that affects their vision.
This study tests whether a blood pressure medication called losartan can affect how people process social situations. It may help researchers understand social behavior better.
This trial studies corneal crosslinking to treat active inflammation or infection that leads to new blood vessels growing into the cornea. It may help reduce ongoing damage and lower the risk of problems, including issues that can threaten a future corneal transplant.
Hear when a new Corneal Scarring Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.